[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Zhang, W., Bai, Y., Sun, C., Lv, Z. and Wang, S. (2022) Racial and Regional Disparities of Triple Negative Breast Cancer Incidence Rates in the United States: An Analysis of 2011-2019 NPCR and SEER Incidence Data. Frontiers in Public Health, 10, Article 1058722. https://doi.org/10.3389/fpubh.2022.1058722
|
[3]
|
Yin, L., Duan, J., Bian, X. and Yu, S. (2020) Triple-negative Breast Cancer Molecular Subtyping and Treatment Progress. Breast Cancer Research, 22, Article No. 61. https://doi.org/10.1186/s13058-020-01296-5
|
[4]
|
Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9, 176-198. https://doi.org/10.1158/2159-8290.cd-18-1177
|
[5]
|
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., et al. (2018) Unravelling Triple-Negative Breast Cancer Molecular Heterogeneity Using an Integrative Multiomic Analysis. Annals of Oncology, 29, 895-902. https://doi.org/10.1093/annonc/mdy024
|
[6]
|
Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. (2011) Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. https://doi.org/10.1172/jci45014
|
[7]
|
Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE, 11, e0157368. https://doi.org/10.1371/journal.pone.0157368
|
[8]
|
Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A.W., et al. (2015) Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 21, 1688-1698. https://doi.org/10.1158/1078-0432.ccr-14-0432
|
[9]
|
Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.E5.
|
[10]
|
Zhao, S., Ma, D., Xiao, Y., Li, X., Ma, J., Zhang, H., et al. (2020) Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. The Oncologist, 25, e1481-e1491. https://doi.org/10.1634/theoncologist.2019-0982
|
[11]
|
Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M.C., Gerratana, L., Tell, G., et al. (2019) Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. International Journal of Molecular Sciences, 20, Article 3390. https://doi.org/10.3390/ijms20143390
|
[12]
|
Torrisi, R., Zuradelli, M., Agostinetto, E., Masci, G., Losurdo, A., De Sanctis, R., et al. (2019) Platinum Salts in the Treatment of Brca-Associated Breast Cancer: A True Targeted Chemotherapy? Critical Reviews in Oncology/Hematology, 135, 66-75. https://doi.org/10.1016/j.critrevonc.2019.01.016
|
[13]
|
Takamizawa, S., Ishiki, H., Shimoi, T., Shimizu, M. and Satomi, E. (2020) Neoadjuvant Cisplatin in BRCA Carriers with HER2-Negative Breast Cancer. Journal of Clinical Oncology, 38, 2699-2700. https://doi.org/10.1200/jco.20.00789
|
[14]
|
Jin, J., Zhang, W., Ji, W., Yang, F. and Guan, X. (2017) Predictive Biomarkers for Triple Negative Breast Cancer Treated with Platinum-Based Chemotherapy. Cancer Biology & Therapy, 18, 369-378. https://doi.org/10.1080/15384047.2017.1323582
|
[15]
|
Chen, Y., Wang, X., Du, F., Yue, J., Si, Y., Zhao, X., et al. (2023) Association between Homologous Recombination Deficiency and Outcomes with Platinum and Platinum-Free Chemotherapy in Patients with Triple-Negative Breast Cancer. Cancer Biology & Medicine, 20, 155-168. https://doi.org/10.20892/j.issn.2095-3941.2022.0525
|
[16]
|
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., et al. (2014) Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. The Lancet Oncology, 15, 747-756. https://doi.org/10.1016/s1470-2045(14)70160-3
|
[17]
|
Sikov, W.M., Berry, D.A., Perou, C.M., et al. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33, 13-21.
|
[18]
|
Rugo, H.S., Olopade, O.I., DeMichele, A., Yau, C., van ’t Veer, L.J., Buxton, M.B., et al. (2016) Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 375, 23-34. https://doi.org/10.1056/nejmoa1513749
|
[19]
|
Li, Z., Zhang, Z., Cao, X., Feng, Y. and Ren, S. (2020) Platinum-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Journal of International Medical Research, 48, No. 10. https://doi.org/10.1177/0300060520964340
|
[20]
|
Filho, O.M., Stover, D.G., Asad, S., Ansell, P.J., Watson, M., Loibl, S., et al. (2021) Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 7, 603-608. https://doi.org/10.1001/jamaoncol.2020.7310
|
[21]
|
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., et al. (2017) Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 3, 1378-1385. https://doi.org/10.1001/jamaoncol.2017.1007
|
[22]
|
Shepherd, J.H., Ballman, K., Polley, M.C., Campbell, J.D., Fan, C., Selitsky, S., et al. (2022) CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival after Neoadjuvant Chemotherapy with or without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 40, 1323-1334. https://doi.org/10.1200/jco.21.01506
|
[23]
|
Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., et al. (2022) Long-term Efficacy and Safety of Addition of Carboplatin with or without Veliparib to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: 4-Year Follow-Up Data from Brightness, a Randomized Phase III Trial. Annals of Oncology, 33, 384-394. https://doi.org/10.1016/j.annonc.2022.01.009
|
[24]
|
Zhao, F., Shen, G., Dong, Q., Xin, Y., Huo, X., Wang, M., et al. (2022) Impact of Platinum-Based Chemotherapy on the Prognosis of Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clinical and Experimental Medicine, 23, 2025-2040. https://doi.org/10.1007/s10238-022-00940-y
|
[25]
|
Dixon-Douglas, J. and Loi, S. (2023) Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed? Current Treatment Options in Oncology, 24, 1004-1020. https://doi.org/10.1007/s11864-023-01087-y
|
[26]
|
Wong, R.S., Ong, R.J. and Lim, J.S. (2023) Immune Checkpoint Inhibitors in Breast Cancer: Development, Mechanisms of Resistance and Potential Management Strategies. Cancer Drug Resistance, 6, 768-787. https://doi.org/10.20517/cdr.2023.58
|
[27]
|
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., et al. (2022) Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 386, 556-567. https://doi.org/10.1056/nejmoa2112651
|
[28]
|
Mittendorf, E.A., Zhang, H., Barrios, C.H., Saji, S., Jung, K.H., Hegg, R., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. https://doi.org/10.1016/s0140-6736(20)31953-x
|
[29]
|
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J., et al. (2022) Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response. Annals of Oncology, 33, 1149-1158. https://doi.org/10.1016/j.annonc.2022.07.1940
|
[30]
|
Cunha, M.T., Gouveia, M.C., Neto, F.L., Testa, L., Hoff, P.M., de Azambuja, E., et al. (2023) Long-Term Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer: An Extracted Individual Patient Data and Trial-Level Meta-Analysis. British Journal of Cancer, 130, 242-250. https://doi.org/10.1038/s41416-023-02501-w
|
[31]
|
Sharma, P., Stecklein, S.R., Yoder, R., Staley, J.M., Schwensen, K., O’Dea, A., et al. (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology, 10, 227-235. https://doi.org/10.1001/jamaoncol.2023.5033
|
[32]
|
Pusztai, L., Yau, C., Wolf, D.M., Han, H.S., Du, L., Wallace, A.M., et al. (2021) Durvalumab with Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results from the Adaptively Randomized I-SPY2 Trial. Cancer Cell, 39, 989-998.E5. https://doi.org/10.1016/j.ccell.2021.05.009
|
[33]
|
Vinayak, S., Tolaney, S.M., Schwartzberg, L., Mita, M., McCann, G., Tan, A.R., et al. (2019) Open-Label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 5, 1132-1140. https://doi.org/10.1001/jamaoncol.2019.1029
|
[34]
|
Jain, P. (2023) Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer with BRCA Gene Mutations: A Narrative Review. Cureus, 15, e46405. https://doi.org/10.7759/cureus.46405
|
[35]
|
Exman, P., Barroso-Sousa, R. and Tolaney, S.M. (2019) Evidence to Date: Talazoparib in the Treatment of Breast Cancer. OncoTargets and Therapy, 12, 5177-5187. https://doi.org/10.2147/ott.s184971
|
[36]
|
Robson, M.E., Tung, N., Conte, P., Im, S., Senkus, E., Xu, B., et al. (2019) Olympiad Final Overall Survival and Tolerability Results: Olaparib versus Chemotherapy Treatment of Physician’s Choice in Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer. Annals of Oncology, 30, 558-566. https://doi.org/10.1093/annonc/mdz012
|
[37]
|
Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K., Gonçalves, A., et al. (2020) Talazoparib versus Chemotherapy in Patients with Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results from the EMBRACA Trial. Annals of Oncology, 31, 1526-1535. https://doi.org/10.1016/j.annonc.2020.08.2098
|
[38]
|
Miricescu, D., Totan, A., Stanescu-Spinu, I., Badoiu, S.C., Stefani, C. and Greabu, M. (2020) PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. International Journal of Molecular Sciences, 22, Article 173. https://doi.org/10.3390/ijms22010173
|
[39]
|
Dong, C., Wu, J., Chen, Y., Nie, J. and Chen, C. (2021) Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 12, Article 628690. https://doi.org/10.3389/fphar.2021.628690
|
[40]
|
Alves, C.L. and Ditzel, H.J. (2023) Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International Journal of Molecular Sciences, 24, Article 4522. https://doi.org/10.3390/ijms24054522
|
[41]
|
Kalimutho, M., Parsons, K., Mittal, D., López, J.A., Srihari, S. and Khanna, K.K. (2015) Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 36, 822-846. https://doi.org/10.1016/j.tips.2015.08.009
|
[42]
|
Oliveira, M., Saura, C., Nuciforo, P., Calvo, I., Andersen, J., Passos-Coelho, J.L., et al. (2019) Fairlane, a Double-Blind Placebo-Controlled Randomized Phase II Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Early Triple-Negative Breast Cancer. Annals of Oncology, 30, 1289-1297. https://doi.org/10.1093/annonc/mdz177
|
[43]
|
Niemeier, L.A., Dabbs, D.J., Beriwal, S., Striebel, J.M. and Bhargava, R. (2010) Androgen Receptor in Breast Cancer: Expression in Estrogen Receptor-Positive Tumors and in Estrogen Receptor-Negative Tumors with Apocrine Differentiation. Modern Pathology, 23, 205-212. https://doi.org/10.1038/modpathol.2009.159
|
[44]
|
Thike, A.A., Yong-Zheng Chong, L., Cheok, P.Y., Li, H.H., Wai-Cheong Yip, G., Huat Bay, B., et al. (2014) Loss of Androgen Receptor Expression Predicts Early Recurrence in Triple-Negative and Basal-Like Breast Cancer. Modern Pathology, 27, 352-360. https://doi.org/10.1038/modpathol.2013.145
|
[45]
|
Jiang, Y., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W., et al. (2020) Molecular Subtyping and Genomic Profiling Expand Precision Medicine in Refractory Metastatic Triple-Negative Breast Cancer: The Future Trial. Cell Research, 31, 178-186. https://doi.org/10.1038/s41422-020-0375-9
|
[46]
|
Yang, C., Zhang, J., Zhang, Y., Ji, F., Chen, Y., Zhu, T., et al. (2022) Low-dose Apatinib Combined with Neoadjuvant Chemotherapy in the Treatment of Early-Stage Triple-Negative Breast Cancer (LANCET): A Single-Center, Single-Arm, Phase II Trial. Therapeutic Advances in Medical Oncology, 14. https://doi.org/10.1177/17588359221118053
|
[47]
|
Spring, L.M., Tolaney, S.M., Fell, G., Bossuyt, V., Abelman, R.O., Wu, B., et al. (2024) Response-Guided Neoadjuvant Sacituzumab Govitecan for Localized Triple-Negative Breast Cancer: Results from the Neostar Trial. Annals of Oncology, 35, 293-301. https://doi.org/10.1016/j.annonc.2023.11.018
|